leisure time -WSS

leisure time

author：focus 2025-09-28 02:32:01 - browse：72469

Adam's take main illustration — Molly Ferguson/STAT

Happy Groundhog Day eve. Some takes and thoughts on Bluebird Bio’s quest for gene therapy profits, a reality check on Vertex’s highly touted pain drug, and more ADC investor FOMO.

Bluebird and the case for gene therapy profits

Genetic treatments that are potential cures for inherited diseases are a huge medical advance, but can these transformational (and expensive) products become a profitable business? I’m not sure anyone knows yet for sure, but pay attention to Bluebird Bio over the next year for some clues.

Bluebird is unique among the biotech and pharma companies selling gene therapies (or CRISPR-based medicines) today because it has no other marketed products. With the recent approval of Lyfgenia for sickle cell disease (cost: $3.1 million), Bluebird sells three gene therapies. The other products are Zynteglo for beta thalassemia ($2.8 million) and Skysona for cerebral adrenoleukodystrophy ($3 million). It’s a pure-play commercial gene therapy business. It’s not even trying to develop additional gene therapies currently. R&D expenses are tied to gathering long-term data on its existing products.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Drug repurposing or repositioning? The language matters
Next article： Radiation, mainstay of cancer treatment, begins a fade

knowledge

hotspot

WSS

Elizabeth Holmes banned from government health programs

The surgeon had a dilemma only a Nazi medical text could resolve

Copay coupons to count toward deductibles, after Biden court move

Prior authorization will have to move faster under new Biden rule

CDC advisory panel says seniors 'may' get RSV vaccine

AstraZeneca challenges Medicare drug negotiation program

focus

leisure time

Bluebird and the case for gene therapy profits

focus

Trump demands the U.S. pay no more for drugs than other countries … again

Drug firms test therapies to halt Alzheimer’s before symptoms arise

Tori Bowie and the unacceptable rates of Black maternal death

Dewpoint Therapeutics lays off staff after losing partnerships

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

2024 GOP presidential candidates spar over abortion in debate

Guidelines to prevent youth baseball injuries need more muscle

AstraZeneca bets AAV gene therapy will still deliver the goods

Cancer drug shortages should be causing more outrage

How Long Island became the ‘eugenics capital of the world’

knowledge

In science, is the line between industry and academia shifting?

Why more medical students aren't specializing in primary care

AstraZeneca bets AAV gene therapy will still deliver the goods

What to make of Gilead’s Trodelvy troubles and Elevation Oncology’s rise

Why doctors need education on FDA device approval process

Australia’s approach to dialysis celebrates life

knowledge

focus

hotspot

explore